European mRNA & Immunotherapy Supply Chain 2026

The European mRNA layer concentrates in Germany. BioNTech in Mainz moved from pre-2020 platform developer to large-scale commercial mRNA manufacturing during the COVID era and now operates across infectious disease and oncology pipelines disclosed publicly. CureVac in Tübingen is the other German mRNA innovator in the directory — an RNA platform with translational and clinical development activity and a published oncology pipeline. Around these two innovators, Germany holds the mRNA CDMO and supply layer the directory surfaces: AGC Biologics Heidelberg publishes mRNA and pDNA manufacturing plus microbial bioprocessing, IDT Biologika Dessau-Rosslau runs viral-vector and vaccine fill-finish at commercial scale, and BioSpring in Frankfurt provides GMP oligonucleotide supply. For a sponsor planning an mRNA programme inside the EU, this is the geography the directory surfaces as most legible.

Switzerland is not an mRNA manufacturer in the BioNTech sense, but it is where one of Europe’s larger synthetic oligonucleotide and peptide API operators sits. Bachem in Bubendorf holds peptide manufacturing at scale, including oligonucleotides and peptide-oligonucleotide conjugates. For programmes that combine synthetic oligo APIs with downstream biologics manufacturing elsewhere, Bachem is one of the European options on the API side. Around Bachem, Swiss pharma anchors (Novartis, Roche) and CDMOs (Lonza, Siegfried) absorb demand and build ADC / conjugate capacity that touches the same API supply.

The Nordic vaccine layer is separate from the German mRNA layer. Bavarian Nordic in Kvistgaard (Denmark) operates biodefence programmes and the MVA-BN vaccine platform, which has regulatory approval for smallpox and monkeypox use. Valneva Sweden in Stockholm holds infectious-disease vaccine capacity. ALK-Abelló in Horsholm operates allergen immunotherapy manufacturing. Statens Serum Institut in Copenhagen runs as Denmark’s public-health reference lab and national vaccine infrastructure. Alongside the broader Nordic immuno-oncology and vaccine-technology layer the directory surfaces (MinervaX, Abera Bioscience, ExpreS2ion, Nykode Therapeutics in Oslo), the Nordics read as a vaccine and immunotherapy group that complements, rather than substitutes, the German mRNA story.

mRNA and immunotherapy programmes move raw materials, APIs, and finished drug product across European borders more than most therapeutic modalities. Synthetic oligonucleotides from Frankfurt or Bubendorf move into formulation and fill-finish in Mainz, Heidelberg, or Dessau-Rosslau; viral-vector campaigns route through IDT Biologika; Nordic vaccine operators ship into the EU single market through GDP-certified logistics (DHL Life Sciences & Healthcare, World Courier, Kuehne+Nagel Healthcare). For sponsors planning a cross-border mRNA or immunotherapy footprint, the logistics layer is already a solved problem — the design work is about matching modality to the right German or Swiss operator, not about whether the supply chain can move the material.

Three decisions drive partner selection. First, the modality: mRNA drug substance (BioNTech captive, CureVac captive, or AGC Biologics as CDMO); oligonucleotide API (Bachem or BioSpring); viral vector (IDT Biologika); MVA-BN (Bavarian Nordic captive); allergen immunotherapy (ALK-Abelló captive). Second, the scale: commercial-scale mRNA in Europe remains concentrated — for clinical-scale, more options open. Third, the geography and regulatory fit: EU-internal for simplicity; Switzerland for premium API with EU-aligned logistics. The Memel Biotech directory entry for each operator links to the current public disclosures so sponsors can verify capability before outreach.